生物活性：Fluvastatin-d6 (sodium) is deuterium labeled Fluvastatin sodium. Fluvastatin sodium (XU 62320) is a first fully synthetic, competitive HMG-CoA reductase inhibitor with an IC50 of 8 nM.
Clinical Trial
NCT NumberSponsorConditionStart DatePhaseNCT00674297Hospital for Special Surgery, New York|University of TexasAntiphospholipid SyndromeMay 2008Phase 2NCT00223041University Hospital Schleswig-HolsteinRenal TransplantationApril 2003Phase 2|Phase 3NCT02518503Canadian Network for Observational Drug Effect Studies, CNODES|Drug Safety and Effectiveness Network, Canada|Canadian Institutes of Health Research (CIHR)Diabetes Mellitus, Type 2|Cardiovascular DiseaseJuly 2012 NCT00132717Organon and CoHypercholesterolemiaJanuary 1, 2005Phase 3NCT00199927Mario Negri Institute for Pharmacological ResearchChronic Nephropathy|Proteinuria|HypertensionMarch 2003Phase 3NCT03510715Sanofi|Regeneron PharmaceuticalsHypercholesterolemiaAugust 31, 2018Phase 3NCT00309257Mario Negri Institute for Pharmacological ResearchAlport SyndromeJanuary 2004Phase 2NCT00814723Medical University of GrazHypercholesterolemiaSeptember 2005Phase 4NCT04285749Case Comprehensive Cancer CenterMalignant MelanomaNovember 6, 2020Early Phase 1NCT00441493Bader, Ted, M.D.|US Department of Veterans AffairsHepatitis CSeptember 2006Not ApplicableNCT03309618University Medical Centre LjubljanaMyocardial InfarctionNovember 2012Not ApplicableNCT00171262NovartisDyslipidemiaAugust 2004Phase 4NCT03510884Sanofi|Regeneron PharmaceuticalsHypercholesterolaemiaMay 31, 2018Phase 3NCT00664742NovartisMetabolic SyndromeSeptember 2006Phase 4NCT00821574NovartisHypertension, DyslypidaemiaJuly 2005Phase 4NCT00223028University Hospital Schleswig-HolsteinRenal TransplantationApril 2005Phase 4NCT00549926Yokohama City University Medical CenterCoronary Disease|HypercholesterolemiaOctober 2007Phase 4NCT00176410University of Leipzig|NovartisAortic Valve StenosisJanuary 2003Phase 2NCT00465322Insel Gruppe AG, University Hospital BernDrug-InteractionsNCT00171327NovartisHypertension|DyslipidemiaJuly 2004Phase 4NCT00752843Corcept TherapeuticsHealthy SubjectsSeptember 2008Phase 1NCT03189511University of Zurich|University of BaselAdipose Tissue, Brown|Insulin Resistance|Clinical TrialMay 31, 2017Phase 4NCT00171275Novartis|Ministry of Health, Czech RepublicCoronary Disease|Myocardial InfarctionNovember 2003Phase 4NCT01551173Novartis Pharmaceuticals|NovartisLipid Metabolism DisordersJanuary 2012Phase 4NCT00421005University of BolognaHeart Transplantation|HypercholesterolemiaNovember 2004Phase 4NCT01681199Beijing Anzhen Hospital|NovartisCoronary Heart Disease|AtherosclerosisJuly 2012Phase 4NCT04029584University of California, San FranciscoDrug-drug InteractionApril 25, 2019Phase 4NCT00385658NovartisDyslipidemiaAugust 2006Phase 4NCT00125125NovartisDyslipidemiaMay 2005Phase 4NCT00487318Bader, Ted, M.D.|US Department of Veterans AffairsChronic Hepatitis CJune 2007Phase 2NCT00136799NovartisMixed Dyslipidemia|HypercholesterolemiaJune 2005Phase 3NCT00416403University of California, San Francisco|National Cancer Institute (NCI)Breast CancerJuly 2006Phase 2NCT01045512Martin-Luther-Universität Halle-Wittenberg|NovartisAging|InflammationOctober 2009Phase 2NCT03393377University Medical Centre LjubljanaAtherosclerosisSeptember 2014Not ApplicableNCT02518516Canadian Network for Observational Drug Effect Studies, CNODES|Drug Safety and Effectiveness Network, Canada|Canadian Institutes of Health Research (CIHR)HypercholesterolemiaJanuary 2011NCT00404287AORTICA GroupAortic Valve StenosisOctober 1, 2006Phase 4NCT01992042University Health Network, TorontoProstate CancerFebruary 2014Phase 2NCT00565474Novartis Pharmaceuticals|NovartisGraft VasculopathySeptember 2001Phase 4NCT00171236NovartisHeterozygous Familial Hypercholesterolemia|Mixed DyslipidemiaOctober 2001Phase 3NCT00138528NovartisMetabolic SyndromeOctober 2004Phase 4NCT00489424Novartis Pharmaceuticals|NovartisOsteoporosisJune 2007Phase 4NCT00814606University of ChicagoHepatitis C|Hepatitis C VirusFebruary 2010Phase 2
分子量：439.48
Formula：C24H19D6FNNaO4
非标记 CAS：93957-55-2
性状：固体
颜色：Light yellow to yellow
中文名称：氟伐他汀钠-d6
运输条件：Room temperature in continental US; may vary elsewhere.
储存方式：Powder：-20°C：3 years，4°C：2 years
In solvent：-80°C：6 months，-20°C：1 month